Founded in 2000, Parioforma is an international business consultancy. We offer a consultancy-based approach and are proud of the strong, interactive and results-focused business partnerships we form with our clients.

1. Market Access
Capabilities
Parioforma Ltd
55 Princes Gate
Exhibition Road
South Kensington
London SW7 2PN
United Kingdom
www.parioforma.com

2. © 2014 Parioforma Ltd.
About Parioforma
• Founded in 2000, Parioforma is an international business consultancy.
2
We assist business units to
maximise the return on research
spending by tailoring projects to
actual needs. In addition we
interpret results into business
implications – what does this
mean for our client?
We work with clients at the
RFP stage to prioritise
research requirements
therefore helping them to
focus on areas which will give
them the greatest return.
We offer a consultancy-based
approach and are proud of
the strong, interactive and
results-focused business
partnerships we form with
our clients.
Studies are frequently divided
into phases providing a built-
in flexibility to direct follow-
on work according to the
results of early findings –
ensuring that resources
remain focused.
We specialise in custom research:

3. © 2014 Parioforma Ltd.
Why work with Parioforma?
3
1. Bespoke studies – tailored needs and timelines.1. Bespoke studies – tailored needs and timelines.
2. Affordable pricing – making budgets go further.2. Affordable pricing – making budgets go further.
3. High quality research – experienced science-based team with 10-25+
years experience in Pharma/ Healthcare industries.
3. High quality research – experienced science-based team with 10-25+
years experience in Pharma/ Healthcare industries.
4. Unique problem solving approach – the Parioforma team is highly
specialised, but diverse in experience and background, enabling
analysis of problems from different perspectives.
4. Unique problem solving approach – the Parioforma team is highly
specialised, but diverse in experience and background, enabling
analysis of problems from different perspectives.
5. Strategic pointers & practical implementable solutions – not just
“over-clever analysis.” Helps clients better understand the research
and the implications for their business.
5. Strategic pointers & practical implementable solutions – not just
“over-clever analysis.” Helps clients better understand the research
and the implications for their business.
Key benefits of working with Parioforma

4. © 2014 Parioforma Ltd.
We cover traditional as well as
emerging & complicated markets
4
From our London base we are able to provide
a global footprint by utilising our extensive
network of associates across:
•North America
•Western Europe
•Australia & Japan
In addition we have strong capabilities in
emerging and complicated markets:
•Central Europe, Baltic States, Russia & CIS
•South East Europe including Turkey
•Middle East & Africa
•Latin America
•India, Pakistan, Malaysia, Thailand, etc.

5. © 2014 Parioforma Ltd.
What we do
5
• At Parioforma we believe that a successful Market Access Strategy
begins with reliable intelligence.
• We are focused on delivering ad hoc actionable global and local market
access intelligence in the fields of pharmaceutical, biotechnology, IVD
and medical devices.
• We provide pragmatic and realistic solutions.

6. © 2014 Parioforma Ltd.
Support services
6
• We specialize in-depth primary and secondary research to support ad
hoc analysis – study design is driven by client needs.
• Pricing and access strategy.
• Revenue scenario testing.
• Payer segmentation and partnership development.
• Commercialization strategy.
• Country specific market access understanding.
• Value gap and value driver analysis.
• Payer evidence generation.
• Value message testing and value proposition
development.
• Early price potential assessment.
• Profiling of disease , prescriber and payer environment.
• Due diligence and commercial opportunity
exploration.
Phase II
Phase III &
Pre-
Launch
Preclinical
& Phase I

7. © 2014 Parioforma Ltd.
Our network
7
In-country
KOL & payer
panels
Local experts
& partners
In-country
boutique
research
agencies
In addition to our core team, Parioforma has built up a
global network of in-country partners and experts in
the healthcare, pharmaceutical, IVD and medical
device industries.
•Parioforma has direct links with in-country KOLs and payers
which can be accessed remotely from the UK.
•The advantage of using local independent partners enables
Parioforma to leverage deep knowledge and insights into
national market situations.
Parioforma
Research
Expertise

8. © 2014 Parioforma Ltd.
Project examples
8
CLIENT ISSUE SOLUTION
UK Global
Pharmaceutical
Company
To understand the decision making
process and evidence requirements
for market access in selected CEE
countries: key organizations, key
individuals, etc.
Key payer decision makers in each
country were identified. A depth
interview programme was carried out
to establish the links, relationships
and level of importance of each of the
individuals and organizations involved.
Results were interpreted for market
access strategy.
Top 5 Global
Pharmaceutical
Company
To evaluate the role and development
of HTA/ economic evaluations in
support of evidence-based decision-
making in selected emerging markets:
CEE, Middle East, Latin America.
The team conducted an in-depth
interview programme with
respondents from government
agencies, ISPOR & INAHTA, academic
health economists. As a result
Parioforma were able to provide the
client with country specific key HTA
strategy pointers.
Leading EU-
Based
Pharmaceutical
Company
To understand the current situation
concerning the use and
implementation of HTA/ economic
evaluations for drug reimbursement
and decision making in Russia.
Extensive primary research was
conducted across the country with
ROSPOR, Roszdraznadzor, top clinical
pharmacologists and foreign and
domestic pharmacos. Results were
leveraged to position Russia in the
evolutionary path of using pharmaco-
economics for setting government
prices and reimbursement criteria.

9. © 2014 Parioforma Ltd.
Project examples
9
CLIENT ISSUE SOLUTION
Leading
Japanese
Pharmaceutical
Company
The need to understand the evidence
required for pricing & reimbursement
of dialysis treatments in selected
emerging EU countries.
The team identified key payer
decision makers in each country and
carried out a depth interview
programme. Results were interpreted
to provide strategy pointers for
market access.
UK-based Global
Biotechnology
Company
New market entry.
To establish a Central and Eastern
European business by utilizing 3rd
party distributors to build a strategic
distribution network and create a CEE
marketing channel for forthcoming
products.
The team leveraged its unique
capability to undertake market
intelligence and evaluation work in
the CEE. Detailed analysis of the
universe of distribution companies in
the region was undertaken as well as
an evaluation of the regulatory and
healthcare environments of the
component countries resulting in a
short-list of priority potential partner
companies.
UK Top 5 Global
Pharmaceutical
Company
The need to understand price controls
and reimbursement barriers in
selected emerging market economies
- Russia, China, Indonesia and Poland.
The team identified and profiled key
KOLs and payers in each country. Local
environments were mapped and an
in-depth analysis of the pricing and
reimbursement tactics was
conducted. Results were interpreted
to develop a generic model for
exploiting price controls.

10. © 2014 Parioforma Ltd.
Emerging market insights
10
• Pharma markets in emerging markets
have been continuously witnessing
robust growth on account of:
– Increasing prevalence of diseases
– Rising healthcare spending
– Increasing affordability
• Political and economic transition since
the 1990s has resulted in many
changes in the health sectors of these
countries.
• Many have adopted social health
insurance (SHI) models in attempts to
move away from centrally planned and
state controlled healthcare financing
and coverage.
• Healthcare reforms have been
accompanied by a need for increased
spending driven by:
– Economic growth
– Ageing populations
– Advances in medical technology
– Expanding expectations on the part of
national populations
• Reforms and increased spending have
brought new challenges highlighting the
need for:
– Cost containment
– Improvements in quality of services
– Improvements in equity of access
– Assurance of rational and transparent
spending decisions
• Until recently, many countries have
implemented new technologies with
little or no regard for costs or
effectiveness but increased attention is
now being paid to the implementation
of measures to manage costs and obtain
better value for money:
– Reimbursement and pricing controls –
e.g. reference pricing systems
– Establishment of positive lists
– Cost sharing – e.g. co-payments
– Adoption of the use of HTA in
healthcare decision making – e.g. listing
status, reimbursement level, pricing,
practice guidelines
– Emerging HTA guidelines

11. © 2014 Parioforma Ltd.
Emerging market insights – HTA
comparisons
11
APPROACH POLAND ISRAEL ARGENTINA
Preferred or
required
assessment
approach
CEA
CUA
BIA
CUA
BIA
CEA
BIA
Choice of
comparator
Most frequently used,
most effective, least
expensive, or no
treatment
Existing standard of
care
Most frequently used
Principle outcome
measures
Mortality
Morbidity
Quality of life
Mortality
Morbidity
Progression free
survival
Quality of life
Mortality
Morbidity
Quality of life
Costs
All direct and indirect
costs
Direct costs Direct costs
Modelling Yes Yes – simple only Yes – simple only
Sensitivity analysis Yes Yes Yes
Abbreviations:
CEA – Cost Effectiveness Analysis; CUA – Cost Utility Analysis; BIA – Budget Impact Analysis

12. © 2014 Parioforma Ltd.
Contact
12